At the AACR Annual Meeting 2025 in Chicago, MaaT Pharma presented new preclinical data for its product MaaT034, demonstrating its immune activation and anti-tumor efficacy.

In tumor-bearing mice, the combination of anti-PD-1 therapy with MaaT034 resulted in an impressive 83.7% reduction in tumor growth, compared to just a 10% reduction with anti-PD-1 alone.

MaaT034 is a next-generation, donor-independent synthetic microbiome therapy designed to enhance patient responses to immunotherapy, particularly in combination with Immune Checkpoint Inhibitors (ICIs).

The AACR Annual Meeting where these findings were presented took place in Chicago, Illinois, from April 25 to 30, 2025.

MaaT Pharma is planning to showcase MaaT034 at several upcoming conferences, including the Swiss Biotech Day and the European Hematology Association Congress.

The therapy significantly increases the production of beneficial metabolites, such as short-chain fatty acids, which contribute to improved gut health and immune response.

MaaT034 is developed using a proprietary co-culturing platform and is designed for large-scale production, targeting specific diseases in oncology.

Upcoming conferences include the Swiss Biotech Day on May 5-6, 2025, and the European Hematology Association Congress from June 12-15, 2025.

Further analysis revealed that MaaT034 replicates the microbial functions of MaaT013, the company's lead asset currently in a Phase 2 trial for metastatic melanoma.

In studies with germ-free mice, 70% of the microbial species from MaaT034 successfully engrafted, ensuring a stable presence of beneficial bacteria in the gut.

MaaT Pharma, founded in 2014 and based in Lyon, France, focuses on developing microbiome-driven therapies to enhance cancer patient survival and has been publicly traded on Euronext Paris since 2021.

The company's platform combines standardized donor-derived therapies with a synthetic microbiome ecosystem technology for targeted diseases.